Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB12 vs Keytruda in Stage IV NSCLC
NCT05668650Phase 3Recruiting
- Sponsor
- Laboratorio Elea Phoenix S.A.
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Pembrox in non-small cell lung cancer (NSCLC), sponsored by Laboratorio Elea Phoenix S.A.. Started Aug 2023; status: recruiting.
02
Drugs
Pembrox
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05668650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668650.